Role of macrophages in host defense against aspergillosis and strategies for immune augmentation

Oncologist

Volumn 12, Issue SUPPL. 2, 2007, Pages 7-13

  Segal, Brahm H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aspergillus; Colony stimulating factor; Macrophage; Review

Indexed keywords

COLONY STIMULATING FACTOR; DECTIN 1; RECOMBINANT GAMMA INTERFERON; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ASPERGILLOSIS; CELLULAR IMMUNITY; CONIDIUM; DENDRITIC CELL; HOST RESISTANCE; HUMAN; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS MACROPHAGE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; ASPERGILLUS FUMIGATUS; IMMUNOLOGY; INNATE IMMUNITY; LUNG MYCOSIS; PHYSIOLOGY;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; HUMANS; IMMUNITY, NATURAL; LUNG DISEASES, FUNGAL; MACROPHAGES, ALVEOLAR;

EID: 38449087458     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-S2-7     Document Type: Review

References (69)

1. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173:707-717.
2. Bhatti Z, Shaukat A, Almyroudis NG et al. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006:162:1-15.
3. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997:175:1459-1466.
4. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-1324.
5. Grow WB, Moreb JS, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15-19.
6. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-808.
7. McWhinney PH, Kibbler CC, Hamon MD et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
8. Yuen KY, Woo PC, Ip MS et al. Stage-specific manifestation of mold infections in bone marrow transplant recipients: Risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997;25:37-42.
9. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002;100:4358-4366.
10. Shaukat A, Bakri F, Young P et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics. Mycopathologia 2005;159:181-188.
11. Segal BH, Kwon-Chung J, Walsh TJ et al. Immunotherapy for fungal infections. Clin Infect Dis 2006;42:507-515.
12. Wasylnka JA, Moore MM. Uptake of Aspergillus fumigatus conidia by phagocytic and nonphagocytic cells in vitro: Quantitation using strains expressing green fluorescent protein. Infect Immun 2002;70:3156-3163.
13. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982;69:617-631.
14. Roilides E, Holmes A, Blake C et al. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-γ. J Infect Dis 1994;170:894-899.
15. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23.
16. Bellocchio S, Montagnoli C, Bozza S et al. The contribution of the toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004;172:3059-3069.
17. Hogaboam CM, Takahashi K, Ezekowitz RA et al. M. Mannose-binding lectin deficiency alters the development of fungal asthma: Effects on airway response, inflammation, and cytokine profile. J Leukoc Biol 2004;75:805-814.
18. Brown GD. Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006;6:33-43.
19. Mukhopadhyay S, Herre J, Brown GD et al. The potential for toll-like receptors to collaborate with other innate immune receptors. Immunology 2004;112:521-530.
20. Underhill DM, Ozinsky A, Hajjar AM et al. The toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999;401:811-815.
21. Ozinsky A, Underhill DM, Fontenot JD et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000;97:13766-13771.
22. Tauszig-Delamasure S, Bilak H. Capovilla M et al. Drosophila MyD88 is required for the response to fungal and Gram-positive bacterial infections. Nat Immunol 2002;3:91-97.
23. Lemaitre B, Nicolas E, Michaut L et al. The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983.
24. Netea MG, VanDerGraafCA, Vonk AG et al. The role of toll-like receptor (TLR)2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002;185:1483-1489.
25. Shoham S, Huang C, Chen JM et al. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcusneoformans polysaccharide capsule. J Immunol 2001; 166:4620-4626.
26. Netea MG. Warris A, Van der Meer JWM et al. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 2003;188:320-326.
27. Wang JE, Warris A, Ellingsen EA et al. Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun 2001;69:2402-2406.
28. Meier A, Kirschning CJ, Nikolaus T et al. Toll-like receptor (TLR)2 and TLR4 are essential for Aspergillus- activation of murine macrophages. Cell Microbiol 2003;5:561-570.
29. Mambula SS, Sau K, Henneke Pet al. Toll-like receptor (TLR) signaling in response lo Aspergillus fumigatus. J Biol Chem 20O2;277:39320-39326.
30. Bellocchio S, Moretti S, Perruccio K et al. TLRs govern neutrophil activity in aspergillosis. J Immunol 2004:173:7406-7415.
31. Bozza S, Montagnoli C, Gaziano R et al. Dendritic cell-based vaccination against opportunistic fungi. Vaccine 2004:22:857-864.
32. Bozza S. Gaziano R, Lipford GB et al. Vaccination of mice against invasive aspergillosis with rtcombmsmX Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect2002;4:1281-1290.
33. Romani L, Bistoni F, Gaziano R et al. Thymosin a 1 activates dendritic cells for antifungal Thl resistance through toll-like receptor signaling. Blood 2004:103:4232-4239.
34. Brown GD, Herre J, Williams DL et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003:197:1119-1124.
35. Brown GD, Taylor PR, Reid DM et al. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002:196:407-412.
36. Brown GD, Gordon S. Immune recognition: A new receptor for beta-glu-cans. Nature 2001 ;413:36-37.
37. Gantner BN, Simmons RM, Canavera SJ et al. Collaborative induction of inflammatory responses by dectin-1 and toll-like receptor 2. J Exp Med 2003:197:1107-1117.
38. Segal BH, DeCarlo ES. Kwon-Chung KJ et al. Aspergillus nidulansinfection in chronic granulomatous disease. Medicine (Baltimore) 1998:77:345-354.
39. Segal BH, Holland SM. Primary phagocy tic disorders of childhood. Pediatr Clin North Am 2000:47:1311-1338.
40. Segal BH, Leto TL, Gallin JI et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000:79:170-200.
41. Steele C, Marrero L, Swain S et al. Alveolar macrophage mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the dectin-1 beta-glucan receptor. J Exp Med 2003:198:1677-1688.
42. Viriyakosol S, Fierer J, Brown GD et al. Innate immunity to the pathogenic fungus Coccidioides posadasii is dependent on toll-like receptor 2 and dectin-1. Infect Immun 2005:73:1553-1560.
43. Hohl TM, Van Epps HL, Rivera A et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog2005:l:e30.
44. GersukGM, Underhill DM, Zhu L et al. Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol 2006; 176:3717-3724.
45. Steele C, Rapaka RR, Metz Aet al. The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigaius. PLoS Pathog 2005;l:e42.
46. Marty FM. Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors oi non-Candidainvasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: A cohort study. Blood 2003;102:2768-2776.
47. Couriel D, Saliba R, Hicks K et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004:104:649-654.
48. Filler SG. Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 2OO5;41(suppl 3): S208-S212.
49. Roilides E, Dimitriadou-Georgiadou A, Sein T el al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998:66:5999-6003.
50. Mehrad B. Strieter RM, Standiford TJ. Role of TNF-a in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999;162: 1633-1640.
51. Guo RF, Ward PA. Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: Insights from the IgG immune complex model. Free Radic Biol Med 2002;33:303-310.
52. Phadke AP, Mehrad B. Cytokines in host defense against Aspergillus:Recent advances. Med Mycol 2005;43(suppl 1 ):S 173-S176.
53. Rowe JM. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections. Clin Infect Dis 1998:26:1290-1294.
54. Rowe JM, Andersen J W, Mazza JJ et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995:86:457 - 462.
55. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. JClin Oncol 2006:24:3187-3205.
56. Roilides E, Uhlig K, Venzon D et al. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatushyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993:61:1185-1193.
57. Roilides E, Sein T, Holmes A et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes againstAspergillusfumigatus. J Infect Dis 1995; 172:1028-1034.
58. Roilides E, Holmes A, Blake C et al. Effects of granulocyte colony-stimulating factor and interferon-y on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995 ;57:651-656.
59. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998:26:1279-1281.
60. Vora S, Purimetla N, Brummer E et al. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor. Antimicrob Agents Chemother 1998:42:907-910.
61. Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: Treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005:56:594-597.
62. Sionov E, Segal E. Polyene and cytokine treatment of experimental aspergillosis. FEMS Immunol Med Microbiol 2003:39:221-227.
63. Gonzalez CE, Lyman CA. Lee S et al. Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillusfumigatus. Cytokine 2001:15:87-95.
64. Nagai H. Guo J, Choi H et al. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995:172:1554-1560.
65. Roilides E, Uhlig K, Venzon D et al. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993:61:4870-4877.
66. Cenci E, Mencacci A, Bacci A et al. Tcell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000:165:381-388.
67. Dignani MC, Rex JH. Chan KW et al. Immunomodulation with inter feron-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 2005:104:199-204.
68. Fleming RV, Anaissie EJ, Kantarjian HM et al. Safety of interferon-gamma plus G-CSF in cancer patients with refractory fungal infections: A pilot study. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 18-October 1.1997.
69. Safdar A. Rodriguez G. Ohmagari N et al. The safety of interferon-γ- lb therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005; 103 :731 -739.